Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Hims & Hers Health (NYSE:HIMS) had its price objective hoisted by Needham & Company LLC from $31.00 to $61.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 18.75% from the company’s current price.

HIMS has been the subject of a number of other reports. Piper Sandler raised their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday, January 6th. Bank of America boosted their target price on Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research report on Thursday, February 20th. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their target price for the company from $24.00 to $25.00 in a report on Friday, January 10th. Finally, Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $30.67.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $51.37 on Tuesday. Hims & Hers Health has a 1 year low of $9.67 and a 1 year high of $72.98. The company’s fifty day moving average price is $35.45 and its 200 day moving average price is $26.08. The company has a market capitalization of $11.22 billion, a PE ratio of 116.75 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,080,275 shares of company stock worth $37,247,354. 17.71% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. SlateStone Wealth LLC raised its position in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares during the period. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the period. Summit Investment Advisors Inc. grew its stake in shares of Hims & Hers Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after buying an additional 628 shares in the last quarter. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares during the period. Finally, Harbour Investments Inc. lifted its position in Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after acquiring an additional 833 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.